ArticleJournal of controlled release : official journal of the Controlled Release Society2009
Biosynthesis and characterization of a novel genetically engineered polymer for targeted gene transfer to cancer cells.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Peptide Nanoparticle-Mediated Combinatorial Delivery of Cancer-Related siRNAs for Synergistic Anti-Proliferative Activity in Triple Negative Breast Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells.Biomaterials · 2018Review
- Development of a Recombinant Multifunctional Biomacromolecule for Targeted Gene Transfer to Prostate Cancer Cells.Biomacromolecules · 2017Article
- Dual-targeted peptide-conjugated multifunctional fluorescent probe with AIEgen for efficient nucleus-specific imaging and long-term tracing of cancer cells.Chemical science · 2017Article
- Production of low-expressing recombinant cationic biopolymers with high purity.Protein expression and purification · 2017Article
- Nano-biomimetic carriers are implicated in mechanistic evaluation of intracellular gene delivery.Scientific reports · 2017Article
- Enzyme/Prodrug Systems for Cancer Gene Therapy.Current pharmacology reports · 2016Article
- Reducing the Visibility of the Vector/DNA Nanocomplexes to the Immune System by Elastin-Like Peptides.Pharmaceutical research · 2015Article
- Controlled release from recombinant polymers.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Current status of gene therapy for breast cancer: progress and challenges.The application of clinical genetics · 2014Review
- Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Systematic engineering of uniform, highly efficient, targeted and shielded viral-mimetic nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2013Article
- Bispecific antibody complex pre-targeted delivery of polymer-drug conjugates for cancer therapy.Drug delivery and translational research · 2012Article
- Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus.Journal of controlled release : official journal of the Controlled Release Society · 2011Article
- HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector.Nanomedicine : nanotechnology, biology, and medicine · 2011Article
- Multivalent protein polymers with controlled chemical and physical properties.Advanced drug delivery reviews · 2010Review
- Development of recombinant cationic polymers for gene therapy research.Advanced drug delivery reviews · 2010Review
- Structure prediction and validation of an affibody engineered for cell-specific nucleic acid targeting.Systems and synthetic biology · 2010Article
- Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.International journal of nanomedicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A novel multi-domain biopolymer was designed and genetically engineered with the purpose to target and transfect cancer cells. The biopolymer contains at precise locations: 1) repeating units of arginine and histidine to condense pDNA and lyse endosome membranes, 2) a HER2 targeting affibody to target cancer cells, 3) a pH responsive fusogenic peptide to destabilize endosome membranes and enhance endosomolytic activity of histidine residues, and 4) a nuclear localization signal to enhance translocation of pDNA towards the cell nucleus. The results demonstrated that the biopolymer was able to condense pDNA into nanosize particles, protect pDNA from serum endonucleases, target HER2 positive cancer cells but not HER2 negative ones, efficiently disrupt endosomes, and effectively reach the cell nucleus of target cells to mediate gene expression. To reduce potential toxicity and enhance biodegradability, the biopolymer was designed to be susceptible to digestion by endogenous furin enzymes inside the cells. The results revealed no significant biopolymer related toxicity as determined by impact on cell viability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.